PRN: Biosimilars Market Report (2016-2025): Demand for Biosimilars Expected to Increase Due to Rise in the Incidence of Diseases - Research and Markets

06/feb/2017 17:10:14 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Biosimilars Market Report (2016-2025): Demand for Biosimilars Expected to Increase Due to Rise in the Incidence of Diseases - Research and Markets


DUBLIN, Feb 6, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Biosimilars Market Report, by Product Types, Application and, Geography - Analysis, Share, Trends, Size, & Forecast 2016 - 2025" report to their offering.

The market for biosimilars offers tremendous growth opportunities for the operating companies to record high revenue growth. Thus, large numbers of key companies such as Hospira, Inc., Teva Pharmaceutical, Amgen, Actavis and others are in constant efforts to develop novel biosimilar and spending huge amount of their profits for research and development activities.

For instance, Hospira, Inc. increasing their research and development expenses on clinical trials to introduce novel biosimilars which would ultimately drive the market growth. Additionally, Amgen, Inc. have strong research pipeline (phase III molecule) for the biosimilar products such as ABP 501, ABP 980 and ABP 215.

Furthermore, demand for biosimilars is also expected to increase due to the rise in the incidence of diseases such as cancer, cardiovascular problem, and others. For these diseases, biosimilars have proven a promising option for the disease diagnosis and mitigation.

Other factors such as rising number of off-patented drugs, positive result of many biosimilar clinical trials and others drive the market growth to a great extent. However, a strict regulatory framework for the biosimilar manufacturers to develop these products restricts companies to invest in this market, leading to hampering the market growth during the future period.

Scope of the Report:

By Product Types:

- Recombinant Non-Glycosylated Proteins

- Recombinant Glycosylated Proteins

- Recombinant Peptides

- Others

By Application:

- Oncology

- Blood Disorders

- Infectious Diseases

- Autoimmune Diseases

- Others

Companies Mentioned:

  • Actavis
  • Amgen
  • Biocon Ltd.
  • Cipla Ltd.
  • Hospira, Inc.
  • Sandoz Pharma
  • Stada Arzneimittel AG
  • Wockhardt Ltd.

Key Topics Covered:

1. Biosimilars- Market Overview

2. Executive Summary

3. Biosimilars- Market Dynamics

4. Biosimilars Market - Industry Analysis

5. Biosimilars- Market Landscape

6. Biosimilars Market - By Product Types

7. Biosimilars Market - By Application

8. Biosimilars Market - By Geography

9. Company Profiles

For more information about this report visit

Media Contact:

Research and Markets

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716


blog comments powered by Disqus è un servizio offerto da Factotum Srl